Fiche publication
Date publication
décembre 2023
Journal
JNCI cancer spectrum
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
Tous les auteurs :
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, Pitre L, Wrobel D, Augereau P, Milani M, Rask S, Solbach C, Pritzker L, Noubir S, Parissenti A, Trudeau M
Lien Pubmed
Résumé
In previously reported retrospective studies, high tumour RNA disruption during neoadjuvant chemotherapy predicted for post-treatment pathologic complete response (pCR) and improved disease-free survival at definitive surgery for primary early breast cancer (EBC). The BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) prospective clinical trial (NCT03524430) seeks to validate these prior findings. Here we report training set (Phase I) findings, including determination of RNA disruption index (RDI) cut-points for outcome prediction in the subsequent validation set (Phase II; 454 patients). In 80 patients of the training set, maximum tumour RDI values for biopsies obtained during neoadjuvant chemotherapy were significantly higher in pCR responders than in patients without pCR post-treatment (p = .008). Moreover, maximum tumour RDI values ≤3.7 during treatment predicted for a lack of pCR at surgery (Negative Predictive Value = 93.3%). These findings support the prospect that on-treatment tumour RNA disruption assessments may effectively predict post-surgery outcome, possibly permitting treatment optimization.
Référence
JNCI Cancer Spectr. 2023 12 19;:
